BASEL, Switzerland,
July 19, 2017 /PRNewswire/ -- Axovant
Sciences (NYSE: AXON) today announced new data from a preclinical
study which suggests that intepirdine may have neuroprotective
properties against vascular injury and neuronal metabolic
dysfunction (poster P4-588). These results, along with other
presentations relating to its intepirdine, nelotanserin and
pipeline programs, were presented at the 2017 Alzheimer's
Association International Conference (AAIC) being held in
London July
16 – 20.
"Dementia of the Alzheimer's type, represents one of the most
complex and important unmet needs in all of medicine," said
David Hung, M.D., chief executive
officer of Axovant. "The neuroprotective properties observed in
this preclinical study of intepirdine are intriguing. We look
forward to further exploring this hypothesis."
In the animal model used in this study, intepirdine demonstrated
neuroprotective effects under hypoxic and hypoglycemic conditions
in an in vitro assay of mixed cortical neuron (MCN) cultures at
clinically relevant concentrations. Specifically, when pre-treated
with intepirdine for 24 hours, a decrease in lactate dehydrogenase
(LDH) release, a surrogate marker of cell death, was observed in
MCN cultures exposed to oxygen and glucose deprivation (p<0.05
at multiple intepirdine concentrations).
Intepirdine is a potent 5HT6 receptor antagonist in development
for the potential treatment of mild to moderate Alzheimer's disease
and Lewy body dementia. Intepirdine works in part by promoting the
release of acetylcholine, a neurotransmitter critical to cognition
and function in patients with Alzheimer's disease. Axovant is
evaluating intepirdine in MINDSET, a global, multi-center,
double-blind, placebo-controlled Phase 3 study in subjects with
mild to moderate Alzheimer's disease who are on stable background
donepezil therapy, and expects to report topline results from this
study in late September 2017.
About Axovant Sciences
Axovant is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative medicines to broadly address multiple forms of dementia
and related neurological disorders. Axovant is developing a
pipeline of late- and early-stage product candidates that focuses
on the cognitive, functional, and behavioral aspects of
debilitating conditions such as Alzheimer's disease, Lewy body
dementia and other neurological disorders. For more information,
visit www.axovant.com.
Forward-Looking Statement
This press release contains
forward-looking statements, including statements regarding
Axovant's expectations about timing of the results for the Phase 3
MINDSET study of intepirdine in subjects with Alzheimer's disease,
the Phase 2b HEADWAY-DLB study of intepirdine in subjects with DLB,
the Phase 2 gait and balance study, the proof of concept and
related studies of RVT-103 and RVT-104, other potential
pre-clinical and clinical studies regarding intepirdine and other
elements of its clinical development and regulatory strategy.
Forward-looking statements can be identified by the words
"believe," "anticipate," "continue", "estimate", "project,"
"expect," "plan," "potential," "intends," "will," "would", "could",
"should" or the negative or plural of these words or other similar
expressions that are predictions or indicate future events, trends
or prospects. Forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to: risks associated with the success,
cost and timing of our product development activities and clinical
trials; the approval and commercialization of our product
candidates intepirdine, nelotanserin, RVT-103, and RVT-104; and
increased regulatory requirements. These statements are subject to
the risk that clinical trial data are subject to differing
interpretations, and regulatory agencies, medical and scientific
experts and others may not share Axovant's views of the clinical
study data. There can be no assurance that the clinical programs
for intepirdine, nelotanserin, RVT-103, or RVT-104 will be
successful in demonstrating safety and/or efficacy, that we will
not encounter problems or delays in clinical development, or that
any of our product candidates will ever receive regulatory approval
or be successfully commercialized.
For a further description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Axovant's
business in general, see the "Risk Factors" section of our annual
report on Form 10-K filed with the Securities and Exchange
Commission on June 13, 2017, and
other filings that Axovant makes with the SEC from time to time.
These forward-looking statements are based on information available
to Axovant as of the date of this press release and speak only as
of the date of this release. Axovant disclaims any obligation to
update these forward-looking statements, except as may be required
by law.
View original
content:http://www.prnewswire.com/news-releases/new-preclinical-data-for-intepirdine-suggests-potential-neuroprotective-properties-300490439.html
SOURCE Axovant Sciences